Evolut Low Risk Trial: TAVR Non-inferior to Surgical AR at 5 Years in Low-Risk Patient With Severe AS
Key Points: In the initial Evolut Low Risk Trial, patients with severe aortic stenosis who were at low surgical risk had noninferior outcomes with TAVR using a self-expanding valve compared…
ALLEPRE: Fully Nursing-Led Heart Health Counseling Program Reduces CV Outcomes After ACS
Key Points Nurses are increasingly responsible for cardiovascular risk management, but randomized data supporting this approach is lacking, especially for secondary prevention. ALLEPRE randomized 2060 hospitalized patients in Italy with…
HERZCHECK: A New Paradigm for Assessing Patients at Risk for Heart Failure
Key Points: Individuals in rural areas have a particularly high prevalence of both clinical and subclinical heart failure (HF). Early detection of individuals at risk of progression to symptomatic HF…
FAIR-HF2 Trial: IV Iron Improves Quality of Life But Not CV Events in Heart Failure
Key Points: Iron deficiency is common in patients with heart failure with reduced ejection fraction (HFrEF) and is associated with worse outcomes. The FAIR-HF2 trial assessed the impact of intravenous…
Pre-Op Digifab Before CABG Prevents Post-Op AKI In Patients At High Risk
KEY POINTS: Ouabain, a cardiac glycoside that is structurally similar to digoxin, has been shown to impair renal function in animal models. This finding suggests that Digifab, which binds to…
The EquiOx Study: Pulse Oximeter Performance Varies by Skin Pigment
Key Points: Small retrospective studies of critically ill adults have shown pulse oximetry levels different by race No large prospective study has shown possible difference in pulse oximetry among darker…
Lorundrostat is Effective and Safe in Patients with Uncontrolled Hypertension : ADVANCE-HTN Trial
Key Points: Hypertension (HTN), a major risk factor for cardiovascular disease, remains uncontrolled in many groups Lorundostat is an aldosterone synthase inhibitor, a novel anti-hypertensive agent that has shown some…
FARES II: PCC Improves Hemostasis and Decreases Transfusions in Adult Cardiac Surgery Patients with Coagulopathy
KEY POINTS: Significant bleeding is a common complication of cardiac surgery. Frozen plasma is the standard therapy but prothrombin complex concentrate offers an alternative treatment option. In the Factor Replacement…
DAPA TAVI: Dapagliflozin Reduced All Cause Death or Worsening HF In Elderly Patients Undergoing TAVI
KEY POINTS: SGLT2 inhibitors reduce admission for heart failure exacerbations. Clinical trials for SGLT2 inhibitors have historically excluded patients with aortic stenosis, a group with high rates of heart failure.…
HOST-BR: 3 Months Of DAPT Might be Reasonable For Both Low- And High-Bleeding Risk Patients After PCI With DES
Key Points After DES placement, guidelines recommend considering shorter DAPT duration (e.g. 1-3 months) for those with high bleeding risk (HBR) and longer DAPT duration (e.g., 3-12 months) for those…
SOUL: Oral Semaglutide Reduced CV Events In High-Risk Patients With T2DM with ASCVD or CKD
Key Points Injectable semaglutide, a GLP-1 receptor agonist, reduces CV events in patients with T2DM, however whether the oral form of semaglutide confers the same CV risk reduction is uncertain.…
Bentracimab Significantly Restored Platelet Function in Patients Taking Ticagrelor and Undergoing Urgent Surgery
Key Points: A major limitation of antithrombotic therapy is the risk of bleeding if a patient requires urgent surgical or invasive procedures as well as the risk of spontaneous hemorrhage.…
Semaglutide Increased Walking Distance in Patients with T2DM and Symptomatic PAD
Key Points: Patients with peripheral artery disease (PAD) in combination with type 2 diabetes (T2D) suffer from significant functional limitations and limited treatments. GLP-RA medications have demonstrated benefits that may…
API-CAT Trial: Extended Reduced-Dose Apixaban Non-Inferior to Full Dose for VTE in Cancer
Key Points: Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients Extended anticoagulation is recommended for cancer patients with VTE, but balancing efficacy and bleeding risk remains…
WARRIOR Trial: Intensive Medical Therapy Didn’t Lower Events in INOCA vs Usual Care
Key Points: In the WARRIOR trial, ~ 2500 women with signs and symptoms of ischemia without obstructive coronary disease (INOCA) were randomized to receive intensive medical therapy for coronary artery…
RIVAWAR Trial: Rivaroxaban Is Comparable to Warfarin for Post-MI Left Ventricular Thrombus
Key Points: Left ventricular thrombus (LVT) is a serious complication following heart attacks, particularly STEMIs, and can lead to systemic embolism or stroke. Warfarin has traditionally been the recommended therapy…
Sodium Zirconium Cyclosilicate Enables MRA Optimization in HFrEF with Hyperkalemia: Insights from the REALIZE-K Trial
Key Points: REALIZE-K trial was a double-blind, placebo-controlled, randomized withdrawal study investigating SZC's ability to maintain normokalemia (NK) and optimize spironolactone therapy (≥25 mg daily) in HFrEF patients with or…
Enhanced Efficiency and Accuracy in Echocardiographic Workflow: Insights from the AI-ECHO RCT
Key Points: AI-ECHO RCT is the first randomized trial to evaluate AI-based automated analysis within a real-world clinical echocardiography workflow. The study demonstrated: Improved Workflow Efficiency: AI-assisted workflows increased the…
Obicetrapib Demonstrates Promising Lipid-Lowering Efficacy and Safety in Heterozygous Familial Hypercholesterolemia: BROOKLYN
Key Points: BROOKLYN was a phase III trial that assessed the safety and effectiveness of obicetrapib as an adjunct to maximally tolerated lipid-modifying therapies, in patients with heterozygous familial hypercholesterolemia…
Acoramidis: Open-Label Extension Data Confirms Sustained Benefits in Transthyretin Cardiac Amyloidosis
Key Points: Sustained Efficacy: Continued improvements in cardiac biomarkers, functional capacity, and symptom relief over extended treatment periods. Safety Profile: Consistent safety findings with no new concerns emerging during long…